Genotype-directed Phase II Study of Irinotecan Dosing in Metastatic Colorectal Cancer (mCRC) Patients Receiving FOLFIRI + Bevacizumab

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Colorectal Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria
Histological or cytological documentation of adenocarcinoma of the colon or rectum
Measurable or non-measurable (but evaluable) disease as defined via RECIST 1.1
Metastatic disease not amenable to surgical resection with curative intent
No prior chemotherapy for metastatic disease
Eastern Cooperative Oncology Group (ECOG) performance status ? 2
Adequate bone marrow, renal and hepatic function
Willing to undergo UGT1A1 genotyping
Negative pregnancy test (urine or serum), within 7 day prior to Day 1 of FOLFIRI in women of childbearing potential
Women of childbearing potential and male subjects must agree to use adequate contraception for the duration of study participation. Adequate contraception is defined as any medically recommended method (or combination of methods) as per standard of care.
Exclusion Criteria
UGT1A1 genotype other than *1/*1, *1/*28, or *28/*28
Known dihydropyrimidine dehydrogenase (DPD) deficiency
Prior treatment with irinotecan and/or bevacizumab
Unable or unwilling to discontinue (and substitute if necessary) use of prohibited drugs for at least 14 days (fruits and juices for at least 7 days) prior to Day 1 of FOLFIRI + bevacizumab initiation (see section 11.2, Appendix B, for list of prohibited drugs)
Inadequately controlled hypertension (defined as systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg)
Prior history of hypertensive encephalopathy
Active cardiac disease including any of the following:
New York Heart Association (NYHA) Grade II or greater congestive heart failure (see section 11.3, Appendix C)
History of myocardial infarction or unstable angina within 6 months prior to Day 1
History of stroke or transient ischemic attack within 6 months prior to Day 1 of FOLFIRI + bevacizumab initiation
Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1 of FOLFIRI + bevacizumab initiation
History of hemoptysis (? 1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1 of FOLFIRI + bevacizumab initiation
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of FOLFIRI + bevacizumab initiation or anticipation of need for major surgical procedure during the course of the study
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1 of FOLFIRI + bevacizumab initiation
History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1 of FOLFIRI + bevacizumab initiation
Serious, non-healing wound, active ulcer, or untreated bone fracture
Proteinuria as demonstrated by: Urine protein: creatinine (UPC) ratio ? 1.0 at screening OR Urine dipstick for proteinuria ? 2+ (patients discovered to have ?2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ? 1g of protein in 24 hours to be eligible)
Any serious uncontrolled medical disorder that would impair the ability of the subject to receive protocol-driven therapy
Other anti-cancer or investigational therapy while patients are on study therapy

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176